Angiogene Inc.

Will companies combining cells and devices for cardiac regeneration win a high-stakes gamble in heart failure, or will they merely lay the scientific foundation for future drug therapies? By Mary Stua

As regulators increase their scrutiny of viral vectors for gene therapy and set the bars for safety ever higher, some industry observers have begun questioning whether gene therapy will ever become a

Business: Radiolabelled DNA for proliferative disorders Using technology that is a cross between gene therapy and radiotherapy, Angiogene Inc. hopes to halt or prevent diseases characterized by exc

The new gene therapy start-ups are learning to live with the technology's limitations—and even to exploit them. by Mary Stuart and Roger Longman The concept of engineering a person's own cells to pump